Clinical trials: Retinal Disorders
Geographic Atrophy Secondary to Age-related Macular Degeneration
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss.
- Trial name
- TES-GAP (NCT07531927)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- 5 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Okuvision GmbH
Age-Related Macular Degeneration
Patient-centred Smartphone AI for Protecting Vision in Macular Disease
Macular disease is the leading cause of blindness in the UK and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month [required in 50% of visits] - these…
- Trial name
- NCT05433766
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- OKKO Health
Central Retinal Vein Occlusion
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years.
- Trial name
- SCORE2 (NCT01969708)
- Testing
- aflibercept, bevacizumab
- Where
- 72 sites in United States
- Volunteers
- 362 people
- Sponsor
- The Emmes Company, LLC
Branch Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with…
- Trial name
- BRIGHTER (NCT01599650)
- Testing
- Ranibizumab, Laser
- Where
- 82 sites in Australia, Canada and 15 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion, Macular Edema
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits.
- Trial name
- NCT01411696
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Allergan
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Retinal Disease
P200TxE Diseased Eye Image Collection
The primary objective is to collect images on the P200TxE device in diseased eyes.
- Trial name
- NCT06269666
- Testing
- P200TxE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Optos, PLC
Retinitis Pigmentosa, Retinal Disease
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
This study "A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection" is an observational…
- Conditions
- Retinitis Pigmentosa, Retinal Disease, Retinal Degeneration
- Trial name
- EXTEND (NCT05921162)
- Testing
- Gene Therapy product:vMCO-I
- Where
- India
- Volunteers
- 11 people
- Sponsor
- Nanoscope Therapeutics Inc.
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Macular Edema, Retinal Vein Occlusion
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion.
- Trial name
- NCT01027650
- Testing
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 121 people
- Sponsor
- Allergan
Neovascular (Wet) Age-Related Macular Degeneration
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.
- Trial name
- NCT07557121
- Testing
- AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Volunteers
- 35 people
- Sponsor
- AiViva BioPharma, Inc.
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
The purpose of this study is: To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 To…
- Trial name
- NCT01521793
- Testing
- QLT091001
- Where
- 6 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- QLT Inc.
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company
Retinitis Pigmentosa, Retinal Dystrophy
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i)…
- Trial name
- NCT05820100
- Testing
- Observational
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nanoscope Therapeutics Inc.
Retinal Detachment
Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment
The purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (FCVB) in the treatment of retinal detachment, based on the multi-center clinical trial.
- Trial name
- NCT01261533
- Testing
- foldable capsular vitreous body(FCVB)
- Where
- 9 sites in China
- Volunteers
- 122 people
- Sponsor
- GuangZhou WeiShiBo Biotechnology Co., ltd
Geographic Atrophy, Age-related Macular Degeneration
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral…
- Trial name
- NCT06961370
- Testing
- RO7669330, Syfovre™, Izervay™
- Where
- 17 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration (ARMD)
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Ranibizumab is derived from a murine monoclonal anti- vascular endothelial growth factor (VEGF) antibody and can penetrate through the many retinal cell layers following intravitreal injection.
- Trial name
- NCT00288561
- Testing
- ranibizumab
- Where
- Switzerland
- Sponsor
- Novartis
Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
This study is designed to prove and confirm the efficacy and safety of multiple injections of human recombinant vascular endothelial growth factor receptor-Fc fusion protein (KH902) in patients with choroidal neovascularization…
- Trial name
- PHOENIX (NCT01436864)
- Testing
- Recombinant Human VEGF Receptor-Fc Fusion Protein
- Where
- 11 sites in China
- Volunteers
- 125 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Retinal Detachment
Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)
A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)
- Trial name
- NCT05414747
- Testing
- ABV-1701, SF6 Gas
- Where
- 4 sites in Australia, Thailand
- Volunteers
- 40 people
- Sponsor
- BioFirst Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.